Targeting the ubiquitin-proteasome system for cancer therapy.

Retracted Expression of concern: Heightened endoplasmic reticulum stress in the lungs of patients with chronic obstructive pulmonary disease: the role of Nrf2-regulated proteasomal activity. Am J Respir Crit Care Med (2009) 2.28

Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer (2010) 1.97

Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget (2011) 1.73

A strategy for modulation of enzymes in the ubiquitin system. Science (2013) 1.43

The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective. Cardiovasc Res (2009) 1.36

Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system. Angew Chem Int Ed Engl (2014) 1.18

FAS-associated factor 1 (FAF1): diverse functions and implications for oncogenesis. Cell Cycle (2009) 1.15

Therapy of human papillomavirus-related disease. Vaccine (2012) 1.11

Translational approaches targeting the p53 pathway for anti-cancer therapy. Br J Pharmacol (2012) 1.04

Can we change the disease biology of multiple myeloma? Leuk Res (2012) 0.98

Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation. J Biol Chem (2011) 0.97

SCF β-TRCP targets MTSS1 for ubiquitination-mediated destruction to regulate cancer cell proliferation and migration. Oncotarget (2013) 0.96

Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression. Angiogenesis (2010) 0.94

The p53 tumor suppressor is stabilized by inhibitor of growth 1 (ING1) by blocking polyubiquitination. PLoS One (2011) 0.90

The deubiquitinating enzyme USP17 is essential for GTPase subcellular localization and cell motility. Nat Commun (2011) 0.89

Negative regulation of DAB2IP by Akt and SCFFbw7 pathways. Oncotarget (2014) 0.87

The role of allostery in the ubiquitin-proteasome system. Crit Rev Biochem Mol Biol (2012) 0.87

Diametrical diseases reflect evolutionary-genetic tradeoffs: Evidence from psychiatry, neurology, rheumatology, oncology and immunology. Evol Med Public Health (2015) 0.85

Loss of a 20S proteasome activator in Saccharomyces cerevisiae downregulates genes important for genomic integrity, increases DNA damage, and selectively sensitizes cells to agents with diverse mechanisms of action. G3 (Bethesda) (2012) 0.84

Proteasome inhibition and its therapeutic potential in multiple myeloma. Biologics (2010) 0.84

Heat stress induces epithelial plasticity and cell migration independent of heat shock factor 1. Cell Stress Chaperones (2012) 0.83

WWP2 is overexpressed in human oral cancer, determining tumor size and poor prognosis in patients: downregulation of WWP2 inhibits the AKT signaling and tumor growth in mice. Oncoscience (2014) 0.83

Development of NS3/4A protease-based reporter assay suitable for efficiently assessing hepatitis C virus infection. Antimicrob Agents Chemother (2009) 0.82

USP2a alters chemotherapeutic response by modulating redox. Cell Death Dis (2013) 0.82

BRIZ1 and BRIZ2 proteins form a heteromeric E3 ligase complex required for seed germination and post-germination growth in Arabidopsis thaliana. J Biol Chem (2010) 0.82

Modification by ubiquitin-like proteins: significance in apoptosis and autophagy pathways. Int J Mol Sci (2012) 0.82

Targeting ubiquitination for cancer therapies. Future Med Chem (2015) 0.82

The E3 ubiquitin ligase CHIP mediates ubiquitination and proteasomal degradation of PRMT5. Biochim Biophys Acta (2015) 0.79

Proteasome inhibitor bortezomib suppresses nuclear factor-kappa B activation and ameliorates eye inflammation in experimental autoimmune uveitis. Mediators Inflamm (2015) 0.79

Saturation scanning of ubiquitin variants reveals a common hot spot for binding to USP2 and USP21. Proc Natl Acad Sci U S A (2016) 0.78

Protein folding, protein homeostasis, and cancer. Chin J Cancer (2011) 0.77

Specific expression of k63-linked ubiquitination of calmodulin-like protein 5 in breast cancer of premenopausal patients. J Cancer Res Clin Oncol (2013) 0.76

Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord. Neuropharmacology (2017) 0.76

Ongoing DNA synthesis in the rat cerebral cortex is regulated by a proteolytic pathway independent of the proteasome and calpains. Invest New Drugs (2009) 0.75

A case of Brooke-Spiegler syndrome with a novel mutation in the CYLD gene in a patient with aggressive non-Hodgkin's lymphoma. J Cancer Res Clin Oncol (2015) 0.75

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42

RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature (2002) 14.63

The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell (1993) 12.41

Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell (2000) 10.90

Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol (2006) 10.74

SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol (1999) 9.92

Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell (1994) 9.48

p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell (1994) 8.90

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer (2006) 8.83

RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci U S A (1999) 7.32

Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet (2007) 7.29

BRCA1 mutations in primary breast and ovarian carcinomas. Science (1994) 6.81

Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature (2003) 6.53

Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science (1999) 6.38

The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature (2003) 6.11

CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature (2003) 6.00

Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science (2007) 5.88

A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc Natl Acad Sci U S A (1995) 5.37

Ubiquitin-binding domains. Biochem J (2006) 5.32

A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet (2003) 4.79

Inactivation of the p53 pathway in retinoblastoma. Nature (2006) 4.57

A hitchhiker's guide to the cullin ubiquitin ligases: SCF and its kin. Biochim Biophys Acta (2004) 4.53

The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem (2001) 4.51

Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell (2006) 4.43

The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet (2001) 4.07

BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene (2006) 3.91

The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev (2005) 3.90

Molecular pathogenesis of Fanconi anemia: recent progress. Blood (2006) 3.76

The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell (2005) 3.47

Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A (1999) 3.43

Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet (2000) 3.42

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41

Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest (2004) 3.40

Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci U S A (2001) 3.24

Proline hydroxylation and gene expression. Annu Rev Biochem (2005) 3.23

Ubiquitination on nonlysine residues by a viral E3 ubiquitin ligase. Science (2005) 3.22

Ubiquitin: roles in protein modification and breakdown. Cell (1983) 3.19

The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev (1999) 3.17

Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A (2001) 2.98

E3-independent monoubiquitination of ubiquitin-binding proteins. Mol Cell (2007) 2.77

Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res (2007) 2.60

Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res (2006) 2.55

Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging. Nature (2007) 2.36

Lactacystin, proteasome function, and cell fate. J Biol Chem (1998) 2.33

Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell (2005) 2.17

Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle (2004) 2.15

N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev (2004) 2.14

A SIM-ultaneous role for SUMO and ubiquitin. Trends Biochem Sci (2008) 2.05

p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res (1995) 1.95

Mechanisms, biology and inhibitors of deubiquitinating enzymes. Nat Chem Biol (2007) 1.90

Proteasome inhibitors: antitumor effects and beyond. Leukemia (2006) 1.87

Mutual interactions between the SUMO and ubiquitin systems: a plea of no contest. Trends Cell Biol (2005) 1.80

RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity. Cancer Res (2007) 1.70

MDM2 and prognosis. Mol Cancer Res (2004) 1.62

The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ (2008) 1.61

E1-L2 activates both ubiquitin and FAT10. Mol Cell (2007) 1.60

Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res (2003) 1.60

A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res (2006) 1.51

Multiubiquitylation by E4 enzymes: 'one size' doesn't fit all. Trends Biochem Sci (2005) 1.46

Mechanisms of MYC stabilization in human malignancies. Cell Cycle (2007) 1.43

Regulating the p53 system through ubiquitination. Oncogene (2004) 1.39

Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo. FEBS Lett (2005) 1.36

The comparative proteomics of ubiquitination in mouse. Genome Res (2003) 1.35

UBE1L2, a novel E1 enzyme specific for ubiquitin. J Biol Chem (2007) 1.25

Ras activity regulates cyclin E degradation by the Fbw7 pathway. Proc Natl Acad Sci U S A (2005) 1.15

Hetero-oligomerization with MdmX rescues the ubiquitin/Nedd8 ligase activity of RING finger mutants of Mdm2. J Biol Chem (2007) 1.08

CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J Biol Chem (2006) 1.01

Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. Int J Cancer (2006) 0.96

Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2. Mol Cancer Ther (2008) 0.92

Identification of inhibitors for MDM2 ubiquitin ligase activity from natural product extracts by a novel high-throughput electrochemiluminescent screen. J Biomol Screen (2008) 0.89

PtdIns(3,5)P2 finds a partner. Dev Cell (2003) 0.77

Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res (2007) 2.60

Functional coupling between the extracellular matrix and nuclear lamina by Wnt signaling in progeria. Dev Cell (2010) 1.90

The Wnt antagonist Frzb-1 regulates chondrocyte maturation and long bone development during limb skeletogenesis. Dev Biol (2002) 1.68

Stromal-epithelial crosstalk regulates kidney progenitor cell differentiation. Nat Cell Biol (2013) 1.64

Aberrant activation, nuclear localization, and phosphorylation of Yes-associated protein-1 in the embryonic kidney and Wilms tumor. Pediatr Blood Cancer (2013) 1.46

Action of Nrf2 and Keap1 in ARE-mediated NQO1 expression by quercetin. Free Radic Biol Med (2007) 1.41

Cited1 and Cited2 are differentially expressed in the developing kidney but are not required for nephrogenesis. Dev Dyn (2007) 1.34

Myb controls G(2)/M progression by inducing cyclin B expression in the Drosophila eye imaginal disc. EMBO J (2002) 1.29

Wnt4 induces nephronic tubules in metanephric mesenchyme by a non-canonical mechanism. Dev Biol (2011) 1.27

Molecular Mechanisms Behind the Chemopreventive Effects of Anthocyanidins. J Biomed Biotechnol (2004) 1.22

STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. Proc Natl Acad Sci U S A (2013) 1.20

Identification of Glis1, a novel Gli-related, Kruppel-like zinc finger protein containing transactivation and repressor functions. J Biol Chem (2002) 1.17

6-(Methylsulfinyl)hexyl isothiocyanate suppresses inducible nitric oxide synthase expression through the inhibition of Janus kinase 2-mediated JNK pathway in lipopolysaccharide-activated murine macrophages. Biochem Pharmacol (2005) 1.14

Echinocystic acid induces apoptosis in HL-60 cells through mitochondria-mediated death pathway. Cancer Lett (2004) 1.13

Identification of novel Wilms' tumor suppressor gene target genes implicated in kidney development. J Biol Chem (2007) 1.13

CITED1 expression in Wilms' tumor and embryonic kidney. Neoplasia (2007) 1.10

A novel Wilms tumor 1 (WT1) target gene negatively regulates the WNT signaling pathway. J Biol Chem (2010) 1.09

Early detection of cysteine rich protein 61 (CYR61, CCN1) in urine following renal ischemic reperfusion injury. Kidney Int (2002) 1.09

Stabilization of p53 is involved in quercetin-induced cell cycle arrest and apoptosis in HepG2 cells. Biosci Biotechnol Biochem (2008) 1.09

Cutting edge: bone morphogenetic protein antagonists Drm/Gremlin and Dan interact with Slits and act as negative regulators of monocyte chemotaxis. J Immunol (2004) 1.07

Rhein induces apoptosis in HL-60 cells via reactive oxygen species-independent mitochondrial death pathway. Arch Biochem Biophys (2003) 1.05

STAT1 activation regulates proliferation and differentiation of renal progenitors. Cell Signal (2010) 1.05

Cited1 is a bifunctional transcriptional cofactor that regulates early nephronic patterning. J Am Soc Nephrol (2005) 1.03

Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. ACS Chem Biol (2007) 1.02

Potential chemopreventive properties of extract from baked sweet potato (Ipomoea batatas Lam. Cv. Koganesengan). J Agric Food Chem (2004) 0.97

Detecting gene-gene interactions in prostate disease in African American men. Infect Agent Cancer (2011) 0.97

SIX2 and CITED1, markers of nephronic progenitor self-renewal, remain active in primitive elements of Wilms' tumor. J Pediatr Surg (2012) 0.94

Potential chemopreventive properties of anthocyanin-rich aqueous extracts from in vitro produced tissue of sweetpotato (Ipomoea batatas L.). J Agric Food Chem (2003) 0.94

Biscembranes from the soft coral Sarcophyton glaucum. J Nat Prod (2006) 0.94

ELR+-CXC chemokines and their receptors in early metanephric development. J Am Soc Nephrol (2007) 0.92

FGF8 is essential for formation of the ductal system in the male reproductive tract. Development (2011) 0.92

Nuclear Kaiso indicates aggressive prostate cancers and promotes migration and invasiveness of prostate cancer cells. Am J Pathol (2012) 0.91

Molecular mechanisms of echinocystic acid-induced apoptosis in HepG2 cells. Biochem Biophys Res Commun (2004) 0.89

Identification of inhibitors for MDM2 ubiquitin ligase activity from natural product extracts by a novel high-throughput electrochemiluminescent screen. J Biomol Screen (2008) 0.89

Inhibition of lipopolysaccharide-induced cyclooxygenase-2 transcription by 6-(methylsulfinyl) hexyl isothiocyanate, a chemopreventive compound from Wasabia japonica (Miq.) Matsumura, in mouse macrophages. Biochem Pharmacol (2005) 0.88

Conditionally immortalized cell line of inducible metanephric mesenchyme. Kidney Int (2003) 0.87

MicroRNA profiling of novel African American and Caucasian Prostate Cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltranferase 1. Oncotarget (2014) 0.87

Nuclear localization of Kaiso promotes the poorly differentiated phenotype and EMT in infiltrating ductal carcinomas. Clin Exp Metastasis (2014) 0.87

Nuclear accumulation of beta-catenin protein indicates activation of wnt signaling in chemically induced rat nephroblastomas. Pediatr Dev Pathol (2010) 0.87

Side population rather than CD133(+) cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells. Mol Cancer (2011) 0.87

Wilms' tumorigenesis is altered by misexpression of the transcriptional co-activator, CITED1. J Pediatr Surg (2007) 0.86

Chronic exposure of renal stem cells to inorganic arsenic induces a cancer phenotype. Chem Res Toxicol (2012) 0.85

Response of cyclin B1 to ionizing radiation: regulation by NF-kappaB and mitochondrial antioxidant enzyme MnSOD. Anticancer Res (2004) 0.85

Chemopreventive functions and molecular mechanisms of garlic organosulfur compounds. Food Funct (2014) 0.84

CITED1 expression in liver development and hepatoblastoma. Neoplasia (2012) 0.84

Molecular Mechanisms Underlying Anti-Inflammatory Actions of 6-(Methylsulfinyl)hexyl Isothiocyanate Derived from Wasabi (Wasabia japonica). Adv Pharmacol Sci (2012) 0.83

CITED1 confers stemness to Wilms tumor and enhances tumorigenic responses when enriched in the nucleus. Oncotarget (2014) 0.83

Linoleic acid metabolite suppresses skin inflammation and tumor promotion in mice: possible roles of programmed cell death 4 induction. Carcinogenesis (2009) 0.83

Expression profiling of genes targeted by bilberry (Vaccinium myrtillus) in macrophages through DNA microarray. Nutr Cancer (2008) 0.83

Myricetin directly targets JAK1 to inhibit cell transformation. Cancer Lett (2008) 0.83

Cytotoxic, antioxidant and antibacterial activities of Varthemia iphionoides Boiss. extracts. J Ethnopharmacol (2006) 0.82

Acetyl derivate of quercetin increases the sensitivity of human leukemia cells toward apoptosis. Biofactors (2009) 0.82

Inhibitory effects and molecular mechanisms of garlic organosulfur compounds on the production of inflammatory mediators. Mol Nutr Food Res (2013) 0.82

Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53. Bioorg Med Chem (2008) 0.82

Microarray and pathway analysis highlight Nrf2/ARE-mediated expression profiling by polyphenolic myricetin. Mol Nutr Food Res (2012) 0.81

Rhein inhibits TPA-induced activator protein-1 activation and cell transformation by blocking the JNK-dependent pathway. Int J Oncol (2003) 0.81

Gene expression profiling and pathway network analysis of hepatic metabolic enzymes targeted by baicalein. J Ethnopharmacol (2012) 0.80

Baicalein induces apoptosis through ROS-mediated mitochondrial dysfunction pathway in HL-60 cells. Int J Mol Med (2004) 0.80

Clarification of the role of quercetin hydroxyl groups in superoxide generation and cell apoptosis by chemical modification. Biosci Biotechnol Biochem (2009) 0.80

Akt is a direct target for myricetin to inhibit cell transformation. Mol Cell Biochem (2009) 0.79

Enzymatic production of caffeic acid by koji from plant resources containing caffeoylquinic acid derivatives. Biosci Biotechnol Biochem (2005) 0.78

Modulation of Nrf2/Keap1 system by Wasabi 6-methylthiohexyl isothiocyanate in ARE-mediated NQO1 expression. Mol Nutr Food Res (2013) 0.78

Down-regulation of von Hippel-Lindau protein in N-nitroso compound-induced rat non-clear cell renal tumors. Cancer Lett (2002) 0.77

Inheritance of susceptibility to induction of nephroblastomas in the Noble rat. Differentiation (2009) 0.77

Effects of 6-(methylsulfinyl)hexyl isothiocyanate on cyclooxygenase-2 expression induced by lipopolysaccharide, interferon-gamma and 12-O-tetradecanoylphorbol-13-acetate. Oncol Rep (2007) 0.77

Molecular mechanism of apoptosis induced by schizandrae-derived lignans in human leukemia HL-60 cells. Food Chem Toxicol (2007) 0.77

Anti-inflammatory activity and molecular mechanism of delphinidin 3-sambubioside, a Hibiscus anthocyanin. Biofactors (2015) 0.76

Effect of cultivation line and peeling on food composition, taste characteristic, aroma profile, and antioxidant activity of Shiikuwasha (Citrus depressa Hayata) juice. J Sci Food Agric (2014) 0.75

Phenolic composition and radical scavenging activity of sweetpotato-derived shochu distillery by-products treated with koji. Biosci Biotechnol Biochem (2004) 0.75

Anti-inflammatory activity and molecular mechanism of Oolong tea theasinensin. Food Funct (2014) 0.75

In vitro anticancer activity of loquat tea by inducing apoptosis in human leukemia cells. Biosci Biotechnol Biochem (2014) 0.75

A genome-wide microarray highlights the antiinflammatory genes targeted by oolong tea theasinensin A in macrophages. Nutr Cancer (2011) 0.75

Protein/peptide transduction in metanephric explant culture. Methods Mol Biol (2014) 0.75

Expression pattern of zinc-finger transcription factor Odd-skipped related 2 in murine development and neonatal stage. Gene Expr Patterns (2013) 0.75